Related references
Note: Only part of the references are listed.Molecular Therapy for Obesity and Diabetes Based on a Long-Term Increase in Hepatic Fatty-Acid Oxidation
Josep M. Orellana-Gavalda et al.
HEPATOLOGY (2011)
A Role of the Bile Salt Receptor FXR in Atherosclerosis
Jurre Hageman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
PPARα: an emerging therapeutic target in diabetic microvascular damage
Anne Hiukka et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels
Maja Stefanovic-Racic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes
Kayo Kuroyanagi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation
Min-Sook Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Auraptene, a citrus fruit compound, regulates gene expression as a PPAR alpha agonist in HepG2 hepatocytes
Nobuyuki Takahashi et al.
BIOFACTORS (2008)
The Metabolic Syndrome
Marc-Andre Cornier et al.
ENDOCRINE REVIEWS (2008)
Farnesol decreases serum triglycerides in rats:: Identification of mechanisms including up-regulation of PPARα and down-regulation of fatty acid synthase in hepatocytes
Robin E. Duncan et al.
LIPIDS (2008)
Lipid accumulation in non-adipose tissue and lipotoxicity
N. A. van Herpen et al.
PHYSIOLOGY & BEHAVIOR (2008)
The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys
H. E. Bays et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects
Fang Zhang et al.
PPAR RESEARCH (2007)
Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase
Thomas Prates Ong et al.
CARCINOGENESIS (2006)
PPARγ and human metabolic disease
RK Semple et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
PPARδ:: a dagger in the heart of the metabolic syndrome
GD Barish et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Going nuclear in metabolic and cardiovascular disease
CK Glass
JOURNAL OF CLINICAL INVESTIGATION (2006)
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
YQ Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Peroxisome proliferator-activated receptor (PPAR)α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue -: Comparison of activation of PPARα, PPAR-γ, and their combination
A Tsuchida et al.
DIABETES (2005)
Phytol directly activates peroxisome proliferator-activated receptor α (PPARα) and regulates gene expression involved in lipid metabolism in PPARα-expressing HepG2 hepatocytes
T Goto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
A peroxisome proliferator-activated receptor α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia
A Reifel-Miller et al.
MOLECULAR ENDOCRINOLOGY (2005)
Isoprenoids:: an evolutionary pool for photoprotection
J Peñuelas et al.
TRENDS IN PLANT SCIENCE (2005)
Regulation of carbohydrate metabolism by the farnesoid X receptor
KR Stayrook et al.
ENDOCRINOLOGY (2005)
PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3
SH Koo et al.
NATURE MEDICINE (2004)
PPARs and the complex journey to obesity
RM Evans et al.
NATURE MEDICINE (2004)
Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor α and γ and reduce insulin resistance
H Yajima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome
T Tanaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α
J Fu et al.
NATURE (2003)
Abietic acid activates peroxisome proliferator-activated receptor-γ (PPARγ) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism
N Takahashi et al.
FEBS LETTERS (2003)
Cross-talk between peroxisome proliferator-activated receptor (PPAR) α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism.: I.: PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling
T Yoshikawa et al.
MOLECULAR ENDOCRINOLOGY (2003)
Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis
H Kim et al.
DIABETES (2003)
Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation
SM Houten et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2003)
Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity
YX Wang et al.
CELL (2003)
PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly
JM Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor
IP Torra et al.
MOLECULAR ENDOCRINOLOGY (2003)
Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes
H Hiyoshi et al.
JOURNAL OF LIPID RESEARCH (2003)
Peroxisome proliferator-activated receptor α (PPARα) influences substrate utilization for hepatic glucose production
J Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice
CJ Chou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor γ
N Takahashi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Dual action of isoprenols from herbal medicines on both PPARγ and PPARα in 3T3-L1 adipocytes and HepG2 hepatocytes
N Takahashi et al.
FEBS LETTERS (2002)
Volatile isoprenoid constituents of fruits, vegetables and herbs cumulatively suppress the proliferation of murine B16 melanoma and human HL-60 leukemia cells
D Tatman et al.
CANCER LETTERS (2002)
Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats -: Comparison with PPAR-γ activation
JM Ye et al.
DIABETES (2001)
Diseases of liporegulation: new perspective on obesity and related disorders
RH Unger et al.
FASEB JOURNAL (2001)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity
M Guerre-Millo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
